User profiles for L. Marchionni

Luigi Marchionni

Associate Professor of Pathology and Laboratory Medicine, Weill Cornell Medicine
Verified email at med.cornell.edu
Cited by 15341

The transcriptional landscape of the mammalian genome

…, S McWilliam, MM Babu, M Madera, L Marchionni… - science, 2005 - science.org
This study describes comprehensive polling of transcription start and termination sites and
analysis of previously unidentified full-length complementary DNAs derived from the mouse …

ARI: The social assistive robot and companion

…, A Di Fava, C Vivas, L Marchionni… - 2020 29th IEEE …, 2020 - ieeexplore.ieee.org
With the world population aging and the number of healthcare users with multiple chronic
diseases increasing, healthcare is becoming more costly, and as such, the need to optimise …

Systematic review: gene expression profiling assays in early-stage breast cancer

L Marchionni, RF Wilson, AC Wolff… - Annals of internal …, 2008 - acpjournals.org
Background: Three gene expression–based prognostic breast cancer tests have been licensed
for use. Purpose: To summarize evidence on the validity and utility of 3 gene expression–…

A Primary Xenograft Model of Small-Cell Lung Cancer Reveals Irreversible Changes in Gene Expression Imposed by Culture In vitro

VC Daniel, L Marchionni, JS Hierman, JT Rhodes… - Cancer research, 2009 - AACR
Traditional approaches to the preclinical investigation of cancer therapies rely on the use of
established cell lines maintained in serum-based growth media. This is particularly true of …

Only three driver gene mutations are required for the development of lung and colorectal cancers

C Tomasetti, L Marchionni, MA Nowak… - Proceedings of the …, 2015 - National Acad Sciences
… have different base pair lengths l 1 , l 2 , …, l n . It is also possible to include the effects of
differing nucleotide compositions by multiplying the various l values by a factor depending on …

Tissue-based genomics augments post-prostatectomy risk stratification in a natural history cohort of intermediate-and high-risk men

…, K Yousefi, E Davicioni, GJ Netto, L Marchionni… - European urology, 2016 - Elsevier
Background Radical prostatectomy (RP) is a primary treatment option for men with intermediate-
and high-risk prostate cancer. Although many are effectively cured with local therapy …

[HTML][HTML] Federated benchmarking of medical artificial intelligence with MedPerf

…, JP Howard, M Rosenthal, L Marchionni… - Nature Machine …, 2023 - nature.com
Medical artificial intelligence (AI) has tremendous potential to advance healthcare by
supporting and contributing to the evidence-based practice of medicine, personalizing patient …

[HTML][HTML] Selective analysis of cancer-cell intrinsic transcriptional traits defines novel clinically relevant subtypes of colorectal cancer

…, E Ficarra, L Marchionni, L Trusolino… - Nature …, 2017 - nature.com
Stromal content heavily impacts the transcriptional classification of colorectal cancer (CRC),
with clinical and biological implications. Lineage-dependent stromal transcriptional …

In vivo liver regeneration potential of human induced pluripotent stem cells from diverse origins

H Liu, Y Kim, S Sharkis, L Marchionni… - Science translational …, 2011 - science.org
Human induced pluripotent stem cells (iPSCs) are a potential source of hepatocytes for liver
transplantation to treat end-stage liver disease. In vitro differentiation of human iPSCs into …

[HTML][HTML] Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFβ enhance the efficacy of cancer immunotherapy

…, R Mehra, S Nimmagadda, L Marchionni… - Nature …, 2018 - nature.com
A majority of cancers fail to respond to immunotherapy with antibodies targeting immune
checkpoints, such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) or programmed death-1 (PD-1)…